Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Ropeginterferon for Patients With JAK2 V617F Clonal Hematopoiesis and High-Risk Features
NCT07249840Phase 1Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Jul 2026
- Primary completion
- Aug 2030
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ropeginterferon alfa-2b, sponsored by Brigham and Women's Hospital. Primary endpoints: Number of patients consented and enrolled at 2 years and Number of participants with treatment-related adverse events at 2 years. Started Jul 2026; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
Beyond the preview
Go deeper on NCT07249840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07249840.